Sign In
Buy ABT
$93.24
+2.73 (+3.02%)
At Close: Jun 25, 2026
American Bio Medica (OTCMKTS:ABMC) & Abbott Laboratories (NYSE:ABT) Head-To-Head Contrast
01:44am, Friday, 06'th Feb 2026
Abbott Laboratories (NYSE: ABT - Get Free Report) and American Bio Medica (OTCMKTS:ABMC - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesse
Abbott recalls glucose sensors after seven deaths linked to faulty readings
10:49am, Wednesday, 04'th Feb 2026
Abbott has recalled certain glucose monitoring sensors after reports linked the devices to seven deaths and 860 serious injuries, the U.S. health regulator said on Wednesday.
5 Goldman Sachs Top Stock Picks Have Huge Upside Potential and Pay Dividends
08:43am, Wednesday, 04'th Feb 2026
Founded in 1869, Goldman Sachs is the world's second-largest investment bank by revenue and ranks 55th on the Fortune 500 list of the largest U.S.
NVST or ABT: Which Is the Better Value Stock Right Now?
12:40pm, Monday, 02'nd Feb 2026
Investors with an interest in Medical - Products stocks have likely encountered both Envista (NVST) and Abbott (ABT). But which of these two companies is the best option for those looking for underval
The Best Dividend King to Buy With $150
11:45am, Monday, 02'nd Feb 2026
Abbott Labs' fourth-quarter report was disappointing, partly due to slow sales growth. But some promising new areas and a recent acquisition could help it on that front.
Abbott: Long-Term Investment Opportunity For Dividend Growth Investors
09:30am, Monday, 02'nd Feb 2026
In reality, Abbott Laboratories is actually a Dividend Aristocrat – a vaunted status reserved for companies that have increased dividends for at least 25 consecutive years. ABT grew its revenue from
Looking for Passive Income in 2026? 3 Dividend Kings to Buy Hand Over Fist
07:15pm, Saturday, 31'st Jan 2026
These companies have a long history of dividend growth, spanning more than 50 years. Passive income is something that rewards investors in any market environment.
Best Dividend Aristocrats For February 2026
04:31am, Saturday, 31'st Jan 2026
Dividend Aristocrats underperformed the S&P 500 in 2025, with NOBL returning 6.82% versus SPY's 17.70%. 2026 began strong for Aristocrats, with NOBL gaining 5.67% in January, outpacing SPY's 1.47%. Di
Stock Market Live January 30, 2026: S&P 500 (SPY) Deep in the Red
06:18am, Friday, 30'th Jan 2026
Live Updates If You have $500,000 Saved, Retirement Could Be Closer Than You Think Retirement can be daunting, but it doesn't need to be. Imagine having an expert in your corner to help you with your
10 Highest Rated Dividend Kings For Generations Of Income
10:10am, Thursday, 29'th Jan 2026
My top 10 Dividend Kings list prioritizes reliability, dividend safety, and attractive valuation for long-term, generational income. Selection criteria include payout ratios under 70%, strong dividend
Abbott Laboratories $ABT Shares Sold by Bank of New York Mellon Corp
05:24am, Wednesday, 28'th Jan 2026
Bank of New York Mellon Corp lowered its stake in shares of Abbott Laboratories (NYSE: ABT) by 0.5% during the third quarter, according to the company in its most recent disclosure with the Securities
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It
10:11am, Monday, 26'th Jan 2026
Zacks.com users have recently been watching Abbott (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
3 Reasons to Buy This Dividend King After Its Steep Sell-Off
06:20am, Monday, 26'th Jan 2026
Abbott's stock plunged after the company reported lower-than-expected Q4 revenue last week. However, Abbott's revenue growth should accelerate in 2026.
Head-To-Head Survey: Abbott Laboratories (NYSE:ABT) vs. DiaSorin (OTCMKTS:DSRLF)
01:46am, Monday, 26'th Jan 2026
DiaSorin (OTCMKTS:DSRLF - Get Free Report) and Abbott Laboratories (NYSE: ABT - Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based o
Best Dividend Kings: January 2026
10:11pm, Sunday, 25'th Jan 2026
Dividend Kings underperformed SPY in 2025, averaging 4.91% total return versus SPY's 17.72%, though 14 Kings outperformed the index. 2026 began strongly for Dividend Kings, up 4.66% through January 23
